retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism Beyond GLP -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based Retatrutide: How the Triple Agonist

A nationwide Medicare program designed to expand access to GLP-1 medications will make the drugs available at a steep discount to eligible beneficiaries which will not include the vast majority of TRICARE For Life (TFL) users

At 1.67mg/mL, a 0.25mg dose requires 15 units instead of 10

"From a patient perspective, the bubble will not burst, and the drugs will not disappear, but we are reaching a point here where for GLP-1s, where vanity and health have collided and have really created a market that was being truly transformative for patients, for health systems, and for everybody," said Ronte

"Its often recommended that individuals who are actively losing weight target something in the range of 1.5 g protein per kilogram of targeted bodyweight